PRESS RELEASE

Q2 2024 — Press release

Q2 2024PDF · 22 pages1.6 MB
For immediate release
$22,447 $ 21,519 4.3%
$4,686 $5,376 (12.8)%
$1.93 $2.05 (5.9)%
6.6%
6.5%
7.1%
$6,840 $6,730 1.6%
$2.82 $2.56 10.2%

-- 1 of 22 --

$12,569 $11,657 7.8% 7.8 — 7.6
9,878 9,862 0.2 5.1 (4.9) 5.3
$22,447 $21,519 4.3% 6.6 (2.3) 6.5
$14,490 $13,731 5.5% 7.8 (2.3) 8.0
7,957 7,788 2.2 4.4 (2.2) 4.0
$22,447 $21,519 4.3% 6.6 (2.3) 6.5

-- 2 of 22 --

$10.68
$0.05
$10.73
($0.68)
$10.05
5.5% – 6.0% / 5.8% 5.5% – 6.0% / 5.8%
$89.2B – $89.6B / $89.4B
6.1% – 6.6% / 6.4%
$88.7B – $89.1B / $88.9B
5.5% – 6.0% / 5.8%
$88.0B – $88.4B / $88.2B
4.7% – 5.2% / 5.0%
$88.0B – $88.4B / $88.2B
4.7% – 5.2% / 5.0%
$10.00 – $10.10 / $10.05
0.8% – 1.8% / 1.3%
$10.60 – $10.75 / $10.68
6.9% – 8.4% / 7.7%
$9.97 – $10.07 / $10.02
0.5% – 1.5% / 1.0%
$10.57 – $10.72 / $10.65
6.6% – 8.1% / 7.4%

-- 3 of 22 --



-- 4 of 22 --



-- 5 of 22 --



-- 6 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine (1)
U.S. 8,510	$ 7,818 8.9 % 8.9 - 16,122	$ 14,841 8.6 % 8.6 -
International 5,980 5,913 1.1 6.4 (5.3) 11,930 12,303 (3.0) 1.0 (4.0)
14,490 13,731 5.5 7.8 (2.3) 28,052 27,144 3.3 5.2 (1.9)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S. 8,510 7,818 8.9 8.9 - 16,122 14,841 8.6 8.6 -
International 5,808 5,628 3.2 8.7 (5.5) 11,733 11,271 4.1 8.5 (4.4)
14,318 13,446 6.5 8.8 (2.3) 27,855 26,112 6.7 8.6 (1.9)
MedTech
U.S. 4,059 3,839 5.7 5.7 - 8,067 7,598 6.2 6.2 -
International 3,898 3,949 (1.3) 3.2 (4.5) 7,711 7,671 0.5 4.6 (4.1)
7,957 7,788 2.2 4.4 (2.2) 15,778 15,269 3.3 5.4 (2.1)
U.S. 12,569 11,657 7.8 7.8 - 24,189 22,439 7.8 7.8 -
International 9,878 9,862 0.2 5.1 (4.9) 19,641 19,974 (1.7) 2.4 (4.1)
Worldwide 22,447 21,519 4.3 6.6 (2.3) 43,830 42,413 3.3 5.2 (1.9)
U.S. 12,569 11,657 7.8 7.8 - 24,189 22,439 7.8 7.8 -
International 9,706 9,577 1.3 6.4 (5.1) 19,444 18,942 2.7 6.9 (4.2)
Worldwide excluding COVID-19 Vaccine (1)	
22,275	$ 21,234 4.9 % 7.2 (2.3) 43,633	$ 41,381 5.4 % 7.4 (2.0)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
SECOND QUARTER SIX MONTHS
Percent Change

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,569	$ 11,657 7.8 % 7.8 - 24,189	$ 22,439 7.8 % 7.8 -
Europe 5,214 5,131 1.6 3.4 (1.8) 10,377 10,721 (3.2) (2.4) (0.8)
Western Hemisphere excluding U.S. 1,212 1,136 6.7 22.6 (15.9) 2,406 2,212 8.8 21.9 (13.1)
Asia-Pacific, Africa 3,452 3,595 (4.0) 1.9 (5.9) 6,858 7,041 (2.6) 3.4 (6.0)
International 9,878 9,862 0.2 5.1 (4.9) 19,641 19,974 (1.7) 2.4 (4.1)
Worldwide 22,447	$ 21,519 4.3 % 6.6 (2.3) 43,830	$ 42,413 3.3 % 5.2 (1.9)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area (ex. COVID-19 Vaccine)
U.S.* 12,569	$ 11,657 7.8 % 7.8 - 24,189	$ 22,439 7.8 % 7.8 -
Europe(1) 5,042 4,846 4.1 6.0 (1.9) 10,180 9,689 5.1 6.0 (0.9)
Western Hemisphere excluding U.S.* 1,212 1,136 6.7 22.6 (15.9) 2,406 2,212 8.8 21.9 (13.1)
Asia-Pacific, Africa* 3,452 3,595 (4.0) 1.9 (5.9) 6,858 7,041 (2.6) 3.4 (6.0)
International 9,706 9,577 1.3 6.4 (5.1) 19,444 18,942 2.7 6.9 (4.2)
Worldwide 22,275	$ 21,234 4.9 % 7.2 (2.3) 43,633	$ 41,381 5.4 % 7.4 (2.0)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine sales
Percent Change
SECOND QUARTER SIX MONTHS
Percent Change
SECOND QUARTER SIX MONTHS

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 22,447	$ 100.0 21,519	$ 100.0 4.3
Cost of products sold 6,869 30.6 6,462 30.0 6.3
Gross Profit 15,578 69.4 15,057 70.0 3.5
Selling, marketing and administrative expenses 5,681 25.3 5,396 25.1 5.3
Research and development expense 3,440 15.3 3,703 17.2 (7.1)
In-process research and development impairments 194 0.9 - 0.0
Interest (income) expense, net (125) (0.6) (109) (0.5)
Other (income) expense, net 653 2.9 (384) (1.8)
Restructuring (13) 0.0 145 0.7
Earnings before provision for taxes on income 5,748 25.6 6,306 29.3 (8.8)
Provision for taxes on income 1,062 4.7 930 4.3 14.2
Net earnings from Continuing Operations 4,686	$ 20.9 5,376	$ 25.0 (12.8)
Net earnings/(loss) from Discontinued Operations, net of tax - (232)
Net earnings 4,686	$ 5,144	$
Net earnings per share (Diluted) from Continuing Operations 1.93	$ 2.05	$ (5.9)
Net earnings/(loss) per share (Diluted) from Discontinued Operations -	$ (0.09)	$
Average shares outstanding (Diluted) 2,422.0 2,625.7
Effective tax rate from Continuing Operations 18.5 % 14.7 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 8,404	$ 37.4 8,005	$ 37.2 5.0
Net earnings from Continuing Operations 6,840	$ 30.5 6,730	$ 31.3 1.6
Net earnings per share (Diluted) from Continuing Operations 2.82	$ 2.56	$ 10.2
Effective tax rate from Continuing Operations 18.6 % 15.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2024 2023

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 43,830	$ 100.0 42,413	$ 100.0 3.3
Cost of products sold 13,380 30.5 13,149 31.0 1.8
Gross Profit 30,450 69.5 29,264 69.0 4.1
Selling, marketing and administrative expenses 10,938 25.0 10,302 24.3 6.2
Research and development expense 6,982 16.0 7,158 16.9 (2.5)
In-process research and development impairments 194 0.4 49 0.1
Interest (income) expense, net (334) (0.8) (95) (0.2)
Other (income) expense, net 3,057 7.0 6,556 15.5
Restructuring 151 0.3 275 0.6
Earnings before provision for taxes on income 9,462 21.6 5,019 11.8 88.5
Provision for taxes on income 1,521 3.5 134 0.3 1,035.1
Net earnings from Continuing Operations 7,941	$ 18.1 4,885	$ 11.5 62.6
Net earnings from Discontinued Operations, net of tax - 191
Net earnings 7,941	$ 5,076	$
Net earnings per share (Diluted) from Continuing Operations 3.27	$ 1.86	$ 75.8
Net earnings per share (Diluted) from Discontinued Operations -	$ 0.07	$
Average shares outstanding (Diluted) 2,428.5 2,630.7
Effective tax rate from Continuing Operations 16.1 % 2.7 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 16,281	$ 37.1 15,541	$ 36.6 4.8
Net earnings from Continuing Operations 13,420	$ 30.6 13,070	$ 30.8 2.7
Net earnings per share (Diluted) from Continuing Operations 5.53	$ 4.97	$ 11.3
Effective tax rate from Continuing Operations 17.6 % 15.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2024 2023

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2024 2023 2024 2023
Net Earnings from Continuing Operations, after tax- as reported $4,686 $5,376 $7,941 $4,885
Pre-tax Adjustments
Litigation related 352 137 3,078 7,037
Intangible Asset Amortization expense 1,106 1,130 2,184 2,252
COVID-19 Vaccine related costs 1 64 165 73 609
Restructuring related 2 (11) 145 160 275
Medical Device Regulation 3 68 85 119 149
Acquisition, integration and divestiture related 452 38 600 80
(Gains)/losses on securities 431 (1) 411 71
IPR&D impairments 194 - 194 49
Tax Adjustments
Tax impact on special item adjustments 4 (437) (307) (1,293) (2,287)
Tax legislation and other tax related (65) (38) (47) (50)
Adjusted Net Earnings from Continuing Operations, after tax $6,840 $6,730 $13,420 $13,070
Average shares outstanding (Diluted) 2,422.0 2,625.7 2,428.5 2,630.7
Adjusted net earnings per share from Continuing Operations (Diluted) $2.82 $2.56 $5.53 $4.97
Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.82 $5.54
Notes:
1
2
3
4
Second Quarter
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory
framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change
and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating
decisions and assessing performance which will be completed during 2024.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Six Months Ended
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19
vaccine contractual commitments.
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This
resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program,
hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) and $145 million expense in the fiscal second quarter of 2023 ($275 million Q2 2023
YTD) include asset divestments and the termination of partnered and non-partnered program costs and asset impairments.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The
restructuring expenses of $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 5.5% 2.2% 4.3%
U.S. 8.9% 5.7% 7.8%
International 1.1% (1.3)% 0.2%
WW Currency (2.3) (2.2) (2.3)
U.S. - - -
International (5.3) (4.5) (4.9)
WW Operational 7.8% 4.4% 6.6%
U.S. 8.9% 5.7% 7.8%
International 6.4% 3.2% 5.1%
Shockwave (1.0) (0.4)
U.S. (2.0) (0.7)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.2 0.6 0.3
U.S. 0.1 1.0 0.5
International 0.2 0.1 0.2
WW Adjusted Operational Ex A&D 8.0% 4.0% 6.5%
U.S. 9.0% 4.7% 7.6%
International 6.6% 3.3% 5.3%
COVID-19 Vaccine 1.0 0.6
U.S. 0.0 0.0
International 2.3 1.3
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 9.0% 4.0% 7.1%
U.S. 9.0% 4.7% 7.6%
International 8.9% 3.3% 6.6%
Adjusted Operational Sales Growth
SECOND QUARTER 2024 ACTUAL vs. 2023 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 3.3% 3.3% 3.3%
U.S. 8.6% 6.2% 7.8%
International (3.0)% 0.5% (1.7)%
WW Currency (1.9) (2.1) (1.9)
U.S. - - -
International (4.0) (4.1) (4.1)
WW Operational 5.2% 5.4% 5.2%
U.S. 8.6% 6.2% 7.8%
International 1.0% 4.6% 2.4%
Shockwave (0.5) (0.2)
U.S. (1.0) (0.3)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.3 0.2
U.S. 0.1 0.6 0.3
International 0.1 0.1 0.1
WW Adjusted Operational Ex A&D 5.3% 5.2% 5.2%
U.S. 8.7% 5.8% 7.8%
International 1.1% 4.7% 2.5%
COVID-19 Vaccine 3.4 2.2
U.S. 0.0 0.0
International 7.5 4.5
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 8.7% 5.2% 7.4%
U.S. 8.7% 5.8% 7.8%
International 8.6% 4.7% 7.0%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2024 ACTUAL vs. 2023 ACTUAL
Segments

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
IMMUNOLOGY
US 2,978	$ 2,865 4.0% 4.0% - 5,431	$ 5,313 2.2% 2.2% -
Intl 1,744 1,631 6.9% 13.2% -6.3% 3,538 3,295 7.4% 12.1% -4.7%
WW 4,722 4,496 5.0% 7.3% -2.3% 8,969 8,608 4.2% 6.0% -1.8%
REMICADE
US 231 277 -16.7% -16.7% - 497 553 -10.1% -10.1% -
US Exports (3) 35 33 7.9% 7.9% - 62 74 -15.4% -15.4% -
Intl 127 152 -16.6% -12.0% -4.6% 268 322 -16.9% -13.2% -3.7%
WW 393 462 -14.9% -13.4% -1.5% 827 949 -12.9% -11.6% -1.3%
SIMPONI / SIMPONI ARIA
US 267 285 -6.3% -6.3% - 521 556 -6.2% -6.2% -
Intl 270 244 10.9% 22.8% -11.9% 569 510 11.7% 21.3% -9.6%
WW 537 529 1.6% 7.1% -5.5% 1,091 1,066 2.3% 7.0% -4.7%
STELARA
US 1,855 1,817 2.1% 2.1% - 3,251 3,268 -0.5% -0.5% -
Intl 1,030 981 5.0% 10.1% -5.1% 2,085 1,974 5.6% 9.1% -3.5%
WW 2,885 2,797 3.1% 4.9% -1.8% 5,336 5,241 1.8% 3.1% -1.3%
TREMFYA
US 589 450 30.8% 30.8% - 1,098 856 28.2% 28.2% -
Intl 317 255 23.9% 30.5% -6.6% 616 489 25.8% 31.0% -5.2%
WW 906 706 28.3% 30.7% -2.4% 1,714 1,346 27.3% 29.2% -1.9%
OTHER IMMUNOLOGY
US 2 4 -51.5% -51.5% - 2 7 -75.4% -75.4% -
Intl 0 0 - - - 0 0 - - -
WW 2 4 -51.5% -51.5% - 2 7 -75.4% -75.4% -
INFECTIOUS DISEASES
US 334 395 -15.4% -15.4% - 658 787 -16.4% -16.4% -
Intl 631 727 -13.1% -11.6% -1.5% 1,128 1,920 -41.3% -40.7% -0.6%
WW 965 1,121 -13.9% -12.9% -1.0% 1,786 2,707 -34.0% -33.7% -0.3%
COVID-19 VACCINE
US 0 0 - - - 0 0 - - -
Intl 172 285 -39.7% -39.7% 0.0% 197 1,032 -80.9% -80.9% 0.0%
WW 172 285 -39.7% -39.7% 0.0% 197 1,032 -80.9% -80.9% 0.0%
EDURANT / rilpivirine
US 8 8 -2.8% -2.8% - 16 17 -7.0% -7.0% -
Intl 288 258 11.5% 13.0% -1.5% 603 529 14.1% 14.4% -0.3%
WW 297 266 11.0% 12.5% -1.5% 620 546 13.4% 13.7% -0.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 321 382 -16.0% -16.0% - 635 760 -16.5% -16.5% -
Intl 117 109 6.5% 9.9% -3.4% 221 208 6.0% 7.8% -1.8%
WW 438 491 -11.0% -10.3% -0.7% 856 968 -11.6% -11.2% -0.4%
OTHER INFECTIOUS DISEASES
US 5 5 18.5% 18.5% - 7 10 -29.4% -29.4% -
Intl 55 74 -25.6% -21.1% -4.5% 107 151 -29.3% -26.0% -3.3%
WW 61 79 -23.1% -18.8% -4.3% 114 161 -29.3% -26.2% -3.1%
% Change	% Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
NEUROSCIENCE
US 1,102 1,029 7.1% 7.1% - 2,156 2,007 7.4% 7.4% -
Intl 679 764 -11.1% -6.0% -5.1% 1,428 1,590 -10.2% -5.2% -5.0%
WW 1,782 1,793 -0.6% 1.5% -2.1% 3,585 3,597 -0.3% 1.9% -2.2%
CONCERTA / Methylphenidate
US 34 64 -47.7% -47.7% - 75 134 -44.3% -44.3% -
Intl 129 143 -9.8% -4.6% -5.2% 265 279 -5.1% -0.2% -4.9%
WW 163 208 -21.5% -17.9% -3.6% 340 414 -17.8% -14.5% -3.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 784 721 8.8% 8.8% - 1,549 1,434 8.0% 8.0% -
Intl 269 310 -13.1% -9.0% -4.1% 561 641 -12.4% -8.8% -3.6%
WW 1,054 1,031 2.2% 3.5% -1.3% 2,110 2,075 1.7% 2.8% -1.1%
SPRAVATO
US 226 144 57.9% 57.9% - 417 255 63.9% 63.9% -
Intl 44 25 73.5% 77.4% -3.9% 78 45 74.6% 76.3% -1.7%
WW 271 169 60.2% 60.8% -0.6% 496 300 65.5% 65.7% -0.2%
OTHER NEUROSCIENCE
US 57 100 -42.5% -42.5% - 115 184 -37.3% -37.3% -
Intl 237 286 -17.0% -10.8% -6.2% 524 625 -16.2% -9.5% -6.7%
WW 294 386 -23.7% -19.1% -4.6% 639 809 -21.0% -15.8% -5.2%
ONCOLOGY
US 2,636 2,069 27.4% 27.4% - 5,019 3,958 26.8% 26.8% -
Intl 2,455 2,329 5.4% 10.8% -5.4% 4,885 4,552 7.3% 11.7% -4.4%
WW 5,090 4,398 15.7% 18.6% -2.9% 9,904 8,510 16.4% 18.7% -2.3%
CARVYKTI
US 167 114 46.5% 46.5% - 307 184 66.8% 66.8% -
Intl 20 3 * * * 36 5 * * *
WW 186 117 59.8% 59.9% -0.1% 343 189 81.5% 81.5% 0.0%
DARZALEX
US 1,641 1,322 24.2% 24.2% - 3,105 2,513 23.6% 23.6% -
Intl 1,237 1,110 11.5% 17.9% -6.4% 2,465 2,182 12.9% 18.4% -5.5%
WW 2,878 2,431 18.4% 21.3% -2.9% 5,570 4,695 18.6% 21.2% -2.6%
ERLEADA
US 318 241 32.2% 32.2% - 603 490 23.0% 23.0% -
Intl 418 326 28.0% 32.8% -4.8% 822 619 32.8% 36.5% -3.7%
WW 736 567 29.8% 32.5% -2.7% 1,425 1,109 28.4% 30.5% -2.1%
IMBRUVICA
US 246 262 -6.4% -6.4% - 511 532 -3.9% -3.9% -
Intl 525 579 -9.4% -5.6% -3.8% 1,043 1,136 -8.3% -5.6% -2.7%
WW 770 841 -8.5% -5.9% -2.6% 1,554 1,668 -6.9% -5.1% -1.8%
TECVAYLI
US 104 82 27.5% 27.5% - 205 139 47.7% 47.7% -
Intl 30 12 * * * 63 18 * * *
WW 135 94 42.9% 43.5% -0.6% 268 157 70.2% 70.2% 0.0%
ZYTIGA / abiraterone acetate
US 11 9 21.6% 21.6% - 20 25 -19.7% -19.7% -
Intl 154 218 -29.6% -23.6% -6.0% 326 447 -27.2% -22.1% -5.1%
WW 165 227 -27.7% -21.9% -5.8% 346 472 -26.8% -22.0% -4.8%
OTHER ONCOLOGY
US 148 40 * * - 267 75 * * -
Intl 71 80 -10.4% -6.0% -4.4% 131 144 -8.5% -5.8% -2.7%
WW 221 120 84.2% 87.2% -3.0% 399 219 82.4% 84.2% -1.8%
% Change	% Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 743 684 8.7% 8.7% - 1,509 1,284 17.5% 17.5% -
Intl 296 289 2.6% 11.2% -8.6% 579 561 3.4% 11.0% -7.6%
WW 1,039 972 6.9% 9.4% -2.5% 2,088 1,844 13.2% 15.5% -2.3%
OPSUMIT
US 373 328 13.7% 13.7% - 729 601 21.3% 21.3% -
Intl 170 179 -5.0% 0.5% -5.5% 339 346 -2.2% 2.5% -4.7%
WW 544 507 7.1% 9.1% -2.0% 1,068 947 12.7% 14.4% -1.7%
UPTRAVI
US 349 338 3.3% 3.3% - 741 642 15.5% 15.5% -
Intl 76 61 24.6% 34.4% -9.8% 152 119 27.6% 36.4% -8.8%
WW 426 399 6.6% 8.1% -1.5% 894 761 17.4% 18.7% -1.3%
OTHER PULMONARY HYPERTENSION
US 20 18 18.8% 18.8% - 38 41 -6.1% -6.1% -
Intl 50 48 3.1% 21.0% -17.9% 89 95 -6.7% 10.2% -16.9%
WW 71 66 7.2% 20.4% -13.2% 127 136 -6.5% 5.3% -11.8%
CARDIOVASCULAR / METABOLISM / OTHER
US 717 776 -7.7% -7.7% - 1,348 1,491 -9.6% -9.6% -
Intl 176 174 0.6% 4.0% -3.4% 373 386 -3.6% -1.9% -1.7%
WW 892 950 -6.2% -5.5% -0.7% 1,721 1,877 -8.3% -8.0% -0.3%
XARELTO
US 587 637 -7.9% -7.9% - 1,105 1,215 -9.1% -9.1% -
Intl - - - - - - - - - -
WW 587 637 -7.9% -7.9% - 1,105 1,215 -9.1% -9.1% -
OTHER
US 129 138 -6.4% -6.4% - 243 275 -11.8% -11.8% -
Intl 176 174 0.6% 4.0% -3.4% 373 386 -3.6% -1.9% -1.7%
WW 305 313 -2.5% -0.6% -1.9% 616 662 -7.0% -6.0% -1.0%
TOTAL INNOVATIVE MEDICINE
US 8,510 7,818 8.9% 8.9% - 16,122 14,841 8.6% 8.6% -
Intl 5,980 5,913 1.1% 6.4% -5.3% 11,930 12,303 -3.0% 1.0% -4.0%
WW 14,490	$ 13,731 5.5% 7.8% -2.3% 28,052	$ 27,144 3.3% 5.2% -1.9%
See footnotes at end of schedule
% Change	% Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
MEDTECH SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
CARDIOVASCULAR (4)
US 1,119	$ 908 23.3% 23.3% - 2,144	$ 1,771 21.1% 21.1% -
Intl 753 712 5.7% 11.2% -5.5% 1,534 1,352 13.4% 18.9% -5.5%
WW 1,873 1,620 15.6% 18.0% -2.4% 3,679 3,123 17.8% 20.2% -2.4%
ELECTROPHYSIOLOGY
US 705 609 15.7% 15.7% - 1,397 1,180 18.4% 18.4% -
Intl 618 587 5.4% 11.1% -5.7% 1,270 1,109 14.6% 20.4% -5.8%
WW 1,323 1,196 10.6% 13.4% -2.8% 2,667 2,288 16.5% 19.4% -2.9%
ABIOMED
US 309 272 13.2% 13.2% - 612 536 14.1% 14.1% -
Intl 72 59 20.7% 25.3% -4.6% 139 119 16.5% 20.0% -3.5%
WW 379 331 14.5% 15.4% -0.9% 750 655 14.5% 15.2% -0.7%
SHOCKWAVE (5)
US 77 - * * - 77 - * * -
Intl 0 - - - - 0 - - - -
WW 77 - * * - 77 - * * -
OTHER CARDIOVASCULAR (4)
US 29 27 12.5% 12.5% - 59 55 7.7% 7.7% -
Intl 64 67 -4.5% -1.0% -3.5% 126 125 0.8% 4.8% -4.0%
WW 93 93 0.3% 2.8% -2.5% 185 180 2.9% 5.7% -2.8%
ORTHOPAEDICS
US 1,422 1,388 2.5% 2.5% - 2,870 2,751 4.3% 4.3% -
Intl 890 878 1.4% 4.5% -3.1% 1,782 1,759 1.3% 3.6% -2.3%
WW 2,312 2,265 2.1% 3.3% -1.2% 4,652 4,510 3.2% 4.0% -0.8%
HIPS
US 265 250 5.8% 5.8% - 535 491 8.9% 8.9% -
Intl 152 147 3.4% 6.8% -3.4% 304 296 2.6% 5.0% -2.4%
WW 417 397 4.9% 6.2% -1.3% 839 787 6.5% 7.4% -0.9%
KNEES
US 230 221 4.2% 4.2% - 472 447 5.5% 5.5% -
Intl 163 142 14.9% 17.7% -2.8% 323 284 13.6% 15.4% -1.8%
WW 394 363 8.4% 9.5% -1.1% 795 731 8.7% 9.4% -0.7%
TRAUMA
US 498 483 3.0% 3.0% - 1,002 974 2.9% 2.9% -
Intl 260 255 2.4% 5.5% -3.1% 521 522 0.0% 2.1% -2.1%
WW 759 739 2.8% 3.8% -1.0% 1,524 1,496 1.9% 2.6% -0.7%
SPINE, SPORTS & OTHER
US 430 433 -0.8% -0.8% - 862 839 2.7% 2.7% -
Intl 314 334 -6.1% -2.9% -3.2% 634 657 -3.5% -1.0% -2.5%
WW 743 766 -3.1% -1.7% -1.4% 1,495 1,495 0.0% 1.1% -1.1%
% Change	% Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
SURGERY
US 995 1,015 -2.0% -2.0% - 1,982 1,990 -0.4% -0.4% -
Intl 1,493 1,580 -5.5% -0.7% -4.8% 2,922 3,039 -3.8% 0.7% -4.5%
WW 2,488 2,594 -4.1% -1.2% -2.9% 4,904 5,028 -2.5% 0.3% -2.8%
ADVANCED
US 466 466 0.1% 0.1% - 912 910 0.2% 0.2% -
Intl 675 757 -10.8% -6.4% -4.4% 1,316 1,430 -8.0% -3.7% -4.3%
WW 1,141 1,222 -6.7% -3.9% -2.8% 2,228 2,340 -4.8% -2.2% -2.6%
GENERAL
US 528 548 -3.7% -3.7% - 1,070 1,079 -0.9% -0.9% -
Intl 818 823 -0.7% 4.5% -5.2% 1,606 1,608 -0.2% 4.7% -4.9%
WW 1,346 1,372 -1.9% 1.2% -3.1% 2,676 2,688 -0.5% 2.4% -2.9%
VISION
US 523 529 -1.2% -1.2% - 1,070 1,087 -1.5% -1.5% -
Intl 763 778 -2.0% 2.2% -4.2% 1,473 1,521 -3.2% 0.6% -3.8%
WW 1,285 1,308 -1.7% 0.8% -2.5% 2,543 2,608 -2.5% -0.3% -2.2%
CONTACT LENSES / OTHER
US 409 409 0.2% 0.2% - 847 853 -0.6% -0.6% -
Intl 509 530 -4.0% 1.2% -5.2% 981 1,039 -5.6% -0.9% -4.7%
WW 918 939 -2.2% 0.7% -2.9% 1,828 1,892 -3.4% -0.8% -2.6%
SURGICAL
US 113 120 -5.8% -5.8% - 223 234 -4.8% -4.8% -
Intl 254 249 2.1% 4.5% -2.4% 492 482 2.1% 4.0% -1.9%
WW 367 369 -0.5% 1.2% -1.7% 715 716 -0.1% 1.1% -1.2%
TOTAL MEDTECH
US 4,059 3,839 5.7% 5.7% - 8,067 7,598 6.2% 6.2% -
Intl 3,898 3,949 -1.3% 3.2% -4.5% 7,711 7,671 0.5% 4.6% -4.1%
WW 7,957	$ 7,788	$ 2.2% 4.4% -2.2% 15,778	$ 15,269 3.3% 5.4% -2.1%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Previously referred to as Interventional Solutions
(5) Acquired on May 31, 2024
% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 18 of 22 --

2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Innovative Medicine
U.S. 8,510	$ 7,818 8.9 % 8.9 - 16,122	$ 14,841 8.6 % 8.6 -
International 5,980 5,913 1.1 6.4 (5.3) 11,930 12,303 (3.0) 1.0 (4.0)
Worldwide 14,490 13,731 5.5 7.8 (2.3) 28,052 27,144 3.3 5.2 (1.9)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International 172 285 (39.7) (39.7) 0.0 197 1,032 (80.9) (80.9) 0.0
Worldwide 172 285 (39.7) (39.7) 0.0 197 1,032 (80.9) (80.9) 0.0
Innovative Medicine excluding COVID-19 Vaccine
U.S. 8,510 7,818 8.9 8.9 - 16,122 14,841 8.6 8.6 -
International 5,808 5,628 3.2 8.7 (5.5) 11,733 11,271 4.1 8.5 (4.4)
Worldwide 14,318 13,446 6.5 8.8 (2.3) 27,855 26,112 6.7 8.6 (1.9)
Worldwide
U.S. 12,569 11,657 7.8 7.8 - 24,189 22,439 7.8 7.8 -
International 9,878 9,862 0.2 5.1 (4.9) 19,641 19,974 (1.7) 2.4 (4.1)
Worldwide 22,447 21,519 4.3 6.6 (2.3) 43,830 42,413 3.3 5.2 (1.9)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International 172 285 (39.7) (39.7) 0.0 197 1,032 (80.9) (80.9) 0.0
Worldwide 172 285 (39.7) (39.7) 0.0 197 1,032 (80.9) (80.9) 0.0
Worldwide
U.S. 12,569 11,657 7.8 7.8 - 24,189 22,439 7.8 7.8 -
International 9,706 9,577 1.3 6.4 (5.1) 19,444 18,942 2.7 6.9 (4.2)
Worldwide excluding COVID-19 Vaccine 22,275	$ 21,234 4.9 % 7.2 (2.3) 43,633	$ 41,381 5.4 % 7.4 (2.0)
Europe 5,214	$ 5,131 1.6 % 3.4 (1.8) 10,377	$ 10,721 (3.2) % (2.4) (0.8)
Europe COVID-19 Vaccine Sales 172 285 (39.7) (39.7) 0.0 197 1,032 (80.9) (80.9) 0.0
Europe excluding COVID-19 Vaccine Sales 5,042	$ 4,846 4.1 % 6.0 (1.9) 10,180	$ 9,689 5.1 % 6.0 (0.9)
Percent Change
SECOND QUARTER
Percent Change
SIX MONTHS
Supplemental Sales Information (Unaudited)
(Dollars in Millions)

-- 19 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 5,459 4,812 1,089 1,671 (800) (177) 5,748 6,306
% to Sales 37.7% 35.0% 13.7% 21.5% -3.6% -0.8% 25.6% 29.3%
Intangible asset amortization expense 694 748 412 382 - - 1,106 1,130
In-process research and development impairments 194 - - - - - 194 -
Litigation related 43 (93) (4) 60 313 170 352 137
Loss/(gain) on securities 70 38 22 (39) 339 - 431 (1)
Restructuring related (63) 145 52 - - - (11) 145
Acquisition, integration and divestiture related 1 - 409 38 42 - 452 38
Medical Device Regulation - - 68 85 - - 68 85
COVID-19 Vaccine related costs 64 165 - - - - 64 165
Adjusted Income Before Tax by Segment From Continuing Operations $ 6,462 5,815 2,048 2,197 (106) (7) 8,404 8,005
% to Sales 44.6% 42.3% 25.7% 28.2% -0.5% 0.0% 37.4% 37.2%
Estimated as of 7/17/2024
As Reported Research and development expense $ 2,722 3,048 718 655 3,440 3,703
% to Sales 18.8% 22.2% 9.0% 8.4% 15.3% 17.2%
Q2 QTD - Income Before Tax and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 20 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 10,428 9,214 2,609 3,080 (3,575) (7,275) 9,462 5,019
% to Sales 37.2% 33.9% 16.5% 20.2% -8.2% -17.2% 21.6% 11.8%
Intangible asset amortization expense 1,392 1,487 792 765 - - 2,184 2,252
In-process research and development impairments 194 - - 49 - - 194 49
Litigation related 43 (93) (4) 60 3,039 7,070 3,078 7,037
Loss/(gain) on securities 15 76 44 (5) 352 - 411 71
Restructuring related 81 275 79 - - - 160 275
Acquisition, integration and divestiture related 48 - 470 80 82 - 600 80
Medical Device Regulation - - 119 149 - - 119 149
COVID-19 Vaccine related costs 73 609 - - - - 73 609
Adjusted Income Before Tax by Segment From Continuing Operations $ 12,274 11,568 4,109 4,178 (102) (205) 16,281 15,541
% to Sales 43.8% 42.6% 26.0% 27.4% -0.2% -0.5% 37.1% 36.6%
Estimated as of 7/17/2024
As Reported Research and development expense $ 5,618 5,826 1,364 1,332 6,982 7,158
% to Sales 20.0% 21.5% 8.6% 8.7% 16.0% 16.9%
Q2 YTD - Income Before Tax and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 21 of 22 --

Second Quarter
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Second Quarter
June 30, 2024
Non-GAAP
Cost of products sold 6,869	$ (1,106) (2) (50) (30) (4) - 5,677
Selling, marketing and admin expenses 5,681 (5) 5,676
Research and development expense 3,440 (15) (33) (10) 3,382
Other (Income) / Expense 653 - (352) - (387) (431) (50) (567)
In-process research and development impairments 194 (194) - -
Restructuring (13) 13 -
Provision for taxes on income 1,062 156 70 43 (6) 125 21 14 14 65 1,564
Net Earnings from Continuing Operations 4,686 950 282 151 (5) 327 410 54 50 (65) 6,840
Second Quarter
July 2, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Second Quarter
July 2, 2023
Non-GAAP
Cost of products sold 6,462	$ (1,130) - (34) 38 - 5,336
Selling, marketing and admin expenses 5,396 (8) 5,388
Research and development expense 3,703 - (44) (46) 3,613
Other (Income) / Expense (384) - (137) - (38) 1 (156) (714)
In-process research and development impairments - - -
Restructuring 145 (145) -
Provision for taxes on income 930 177 29 - 37 12 (1) 15 38 38 1,275
Net Earnings from Continuing Operations 5,376 953 108 - 108 26 - 71 126 (38) 6,730
Six Months
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Six Months
June 30, 2024
Non-GAAP
Cost of products sold 13,380	$ (2,184) (9) (50) (50) (6) 11,081
Selling, marketing and admin expenses 10,938 (9) - 10,929
Research and development expense 6,982 (33) (60) (17) 6,872
Other (Income) / Expense 3,057 - (3,078) - (517) (411) (50) (999)
In-process research and development impairments 194 (194) - - - - -
Restructuring 151 (151) -
Provision for taxes on income 1,521 304 697 43 33 163 14 23 16 47 2,861
Net Earnings from Continuing Operations 7,941 1,880 2,381 151 127 437 397 96 57 (47) 13,420
Six Months
July 2, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Six Months
July 2, 2023
Non-GAAP
Cost of products sold 13,149	$ (2,248) - (57) (168) 10,676
Selling, marketing and admin expenses 10,302 (15) 10,287
Research and development expense 7,158 (16) (78) (62) 7,002
Other (Income) / Expense 6,556 (4) (7,037) - (64) (71) (378) (998)
In-process research and development impairments 49 (49) - -
Restructuring 275 (275) -
Provision for taxes on income 134 354 1,651 11 69 17 15 27 143 50 2,471
Net Earnings from Continuing Operations 4,885 1,898 5,386 38 206 63 56 123 465 (50) 13,070
In-process
research and
development
impairments
(Loss)/gain on
securities
Tax legislation
and other tax
related
In-process
research and
development
impairments
COVID-19
Vaccine
Related Costs
COVID-19
Vaccine
Related Costs
COVID-19
Vaccine
Related Costs
COVID-19
Vaccine
Related Costs
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
Year to Date
In-process
research and
development
impairments
(Loss)/gain on
securities
Tax legislation
and other tax
related
Acquisition, integration
and divestiture related
Acquisition, integration
and divestiture related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
(Loss)/gain on
securities
In-process
research and
development
impairments
Tax legislation
and other tax
related
Acquisition, integration
and divestiture related

-- 22 of 22 --